IRIS
FRANCHINA, Tindara
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 5.900
NA - Nord America 5.888
AS - Asia 2.574
SA - Sud America 842
Continente sconosciuto - Info sul continente non disponibili 207
AF - Africa 82
OC - Oceania 4
Totale 15.497
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.711
RU - Federazione Russa 2.960
SG - Singapore 1.042
CN - Cina 734
BR - Brasile 711
SE - Svezia 606
IE - Irlanda 586
IT - Italia 437
PL - Polonia 302
FR - Francia 298
HK - Hong Kong 276
DE - Germania 182
VN - Vietnam 146
GB - Regno Unito 125
UA - Ucraina 122
FI - Finlandia 102
IN - India 85
CA - Canada 74
BD - Bangladesh 54
AT - Austria 46
AR - Argentina 43
MX - Messico 35
BE - Belgio 33
ID - Indonesia 30
IQ - Iraq 28
ZA - Sudafrica 28
TR - Turchia 25
EC - Ecuador 24
UZ - Uzbekistan 24
CO - Colombia 19
NL - Olanda 19
JP - Giappone 16
PH - Filippine 16
VE - Venezuela 16
ES - Italia 15
JM - Giamaica 15
PK - Pakistan 14
CR - Costa Rica 12
NP - Nepal 12
CZ - Repubblica Ceca 11
MA - Marocco 11
CL - Cile 9
EE - Estonia 9
AL - Albania 8
SA - Arabia Saudita 8
AE - Emirati Arabi Uniti 7
IL - Israele 7
LT - Lituania 7
TN - Tunisia 7
CI - Costa d'Avorio 6
DZ - Algeria 6
EG - Egitto 6
EU - Europa 6
KE - Kenya 6
MY - Malesia 6
PY - Paraguay 6
BO - Bolivia 5
GP - Guadalupe 5
GT - Guatemala 5
JO - Giordania 5
TT - Trinidad e Tobago 5
UY - Uruguay 5
BG - Bulgaria 4
CW - ???statistics.table.value.countryCode.CW??? 4
DO - Repubblica Dominicana 4
HN - Honduras 4
KG - Kirghizistan 4
KZ - Kazakistan 4
LK - Sri Lanka 4
PA - Panama 4
PR - Porto Rico 4
RO - Romania 4
SV - El Salvador 4
CH - Svizzera 3
HR - Croazia 3
IR - Iran 3
NI - Nicaragua 3
PE - Perù 3
RS - Serbia 3
SY - Repubblica araba siriana 3
AM - Armenia 2
AO - Angola 2
AU - Australia 2
AZ - Azerbaigian 2
GA - Gabon 2
GE - Georgia 2
LB - Libano 2
LV - Lettonia 2
MD - Moldavia 2
NG - Nigeria 2
NO - Norvegia 2
OM - Oman 2
PS - Palestinian Territory 2
SC - Seychelles 2
SK - Slovacchia (Repubblica Slovacca) 2
TH - Thailandia 2
XK - ???statistics.table.value.countryCode.XK??? 2
AI - Anguilla 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
Totale 15.281
Salva come PNG Salva come JPEG
Città #
Moscow 840
Ashburn 818
Dublin 583
Singapore 548
Chandler 489
Dallas 440
San Jose 314
Nyköping 294
Warsaw 291
Hong Kong 276
Jacksonville 246
Beijing 245
Council Bluffs 165
New York 154
The Dalles 137
Los Angeles 130
Messina 127
Ann Arbor 97
Princeton 94
Dearborn 93
Lauterbourg 83
Medford 82
Cambridge 74
Des Moines 72
São Paulo 56
Santa Clara 54
Buffalo 48
Ho Chi Minh City 46
Munich 44
Boardman 41
Vienna 39
Tianjin 37
Woodbridge 36
Brussels 33
Atlanta 28
Frankfurt am Main 28
Orem 28
Pune 28
Phoenix 27
Chicago 26
Dong Ket 24
Montreal 23
San Mateo 23
Wilmington 23
Brooklyn 22
Jinan 22
Rome 22
Hanoi 21
Shenyang 21
Tashkent 21
Redondo Beach 20
San Francisco 20
London 19
Belo Horizonte 18
Guangzhou 18
Houston 18
Jakarta 18
Turku 18
Chennai 17
Lancaster 17
North Bergen 17
Stockholm 17
Brasília 16
Johannesburg 16
Nanjing 16
Rio de Janeiro 16
Denver 15
Helsinki 15
Fort Washington 14
Grammichele 14
Milan 14
Shanghai 14
Tokyo 14
Boston 13
Toronto 13
Amsterdam 12
Curitiba 12
Hebei 12
Mexico City 12
Quito 12
Catania 11
Manchester 11
Memphis 11
Campinas 10
Columbus 10
Newark 10
Nuremberg 10
Porto Alegre 10
Shenzhen 10
Taizhou 10
Caracas 9
Miami 9
Mumbai 9
Paternò 9
San José 9
Seattle 9
Zhengzhou 9
Baghdad 8
Duque de Caxias 8
Düsseldorf 8
Totale 8.170
Salva come PNG Salva come JPEG
Nome #
Corticosteroids in oncology: Use, overuse, indications, contraindications. An Italian Association of Medical Oncology (AIOM)/ Italian Association of Medical Diabetologists (AMD)/ Italian Society of Endocrinology (SIE)/ Italian Society of Pharmacology (SIF) multidisciplinary consensus position paper 444
Neuropsychiatric Adverse Events with Monoclonal Antibodies Approved for Multiple Myeloma: An Analysis from the FDA Adverse Event Reporting System 270
A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): old successes and future perspectives 252
Prognostic value of methlylenetetrahydrofolate reductase (MTHFR), thymidylate synthase (TS) promoter, and p53 codon 72 variants and survival in advanced non-small cell lung cancer (NSCLC). 249
Safety profile of tyrosine kinase inhibitors used in non-small-cell lung cancer: An analysis from the Italian pharmacovigilance database 243
Androgen Receptor (AR), E-Cadherin, and Ki-67 as emerging targets and novel prognostic markers in triple-negative breast cancer (TNBC) patients 240
Activity of pegylated liposomal doxorubicin in combination with gemcitabine in triple negative breast cancer with skin involvement: Two case reports. 227
Androgen receptor (AR), E-cadherin, and Ki-67 as prognostic markers in triple-negative breast cancer (TNBC). 222
Baseline neutrophilia, derived neutrophil-to-lymphocyte ratio (dNLR), platelet-to-lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with Nivolumab or Docetaxel 222
The prognostic significance of combined androgen receptor, E-Cadherin, Ki67 and CK5/6 expression in patients with triple negative breast cancer 213
Activity and safety of gefitinib and erlotinib in metastatic non-small cell lung cancer (NSCLC): A comparative analysis. 205
Impact of integrated treatments on patient management in solid tumors: from diagnosis to palliative care. 202
Folate pathway implications in advanced Non Small Cell Lung Cancer (NSCLC): impact of thymidylate synthase (TS) promoter and methlylenetetrahydrofolate reductase (MTHFR) C677T and A1298C variants expression on patients’ outcome and correlation with p53 codon 72 mutations. 198
Efficacy of nab-paclitaxel plus trastuzumab in a long-surviving heavily pretreated HER2-positive breast cancer patient with brain metastases 194
Heterogeneous responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with uncommon EGFR mutations: New insights and future perspectives in this complex clinical scenario 191
Circulating miR-22, miR-24 and miR-34a as novel predictive biomarkers to pemetrexed-based chemotherapy in advanced non small cell lung cancer. 187
A new method for titration of oral transmucosal fentanyl citrate (OTFC) starting dose in cancer patients. 186
Emerging role of Radium-223 in the growing therapeutic armamentarium of metastatic castration-resistant prostate cancer 184
Vaginal Mucosal Melanoma: a Complete Remission after Immunotherapy and '0-7-21' Radiotherapy Regimen (24 Gy/3 fractions/21 days) 182
Brain metastases in patients with non-small cell lung cancer: focus on the role of chemotherapy. 180
Central nervous system involvement in ALK-rearranged NSCLC: promising strategies to overcome crizotinib resistance 180
Clinical significance of circulating interleukin-23 as a prognostic factor in breast cancer patients. 179
Can we better manage advanced NSCLC in the elderly with the new therapeutic agents? Preliminary analysis of a real life multicenter study. 179
Gefitinib versus Erlotinib treatment in Non Small Cell Lung Cancer (NSCLC): comparison of two clinical experiences. 178
Correction: Androgen Receptor (AR), E-cadherin, and Ki-67 as emerging targets and novel prognostic markers in Triple-Negative Breast Cancer (TNBC) patients 178
Second-line therapy in advanced non-small cell lung cancer: Cytotoxic agents or tyrosine kinase inhibitors? Our experience. 175
Adverse Drug Reactions with HER2-Positive Breast Cancer Treatment: An Analysis from the Italian Pharmacovigilance Database 175
Epidermal growth factor receptor (EGFR) G719C mutation as new determinant of long term survival and response in patients with non small cell lung cancer treated with erlotinib: 171
The palliative role of Gefitinib (Iressa) in the treatment of heavily pretreated patients with advanced, refractory non small cell lung cancer. Results of a 3-year experience. 170
Is the adenocarcinoma subtype a predictor of response to Pemetrexed in patients with non small cell lung cancer? Our preliminary data 170
Author Correction to: Prevalence of Use and Cost of Biological Drugs for Cancer Treatment: A 5-Year Picture from Southern Italy 170
Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: New directions for systemic therapy - a case report and literature review 169
Is the adenocarcinoma subtype a predictor of response to Pemetrexed in patients with non small cell lung cancer? Our preliminary data. 166
Induction chemotherapy with paclitaxel and cisplatin to concurrent radiotherapy and weekly paclitaxel in the treatment of loco-regionally advanced, stage IV (M0), head and neck squamous cell carcinoma. Mature results of a prospective study. 165
Nab-paclitaxel and trastuzumab combination: A promising approach for neoadjuvant treatment in HER2-positive breast cancer 162
Influence of EGFR mutational status on metastatic behavior in non squamous non small cell lung cancer 161
Challenges and promises of physical exercise in advances lung cancer patients 161
Predicting sensitivity of non small cell lung cancer to gefitinib and erlotinib: is there still a role for clinical factors ? 159
IL-33/IL-31 axis: A new pathological mechanism for epidermal growth factor receptor tyrosine kinase inhibitors-associated skin toxicity? 159
Impact of integrated treatments on patient management in solid tumors: From diagnosis to palliative care. 157
Role of Androgen Receptor (AR), Ki 67 and E-cadherin as prognostic markers in Triple Negative Breast Cancer (TNBC) 156
Third generation EGFR TKIs in EGFR-mutated NSCLC: Where are we now and where are we going 156
The changing scenario of 1st line therapy in non-oncogene addicted NSCLCs in the era of immunotherapy 155
Long time response with chemotherapy in ROS1 NSCLC patient with unusual metastatic site 153
Embolia polmonare 152
Impact of erlotinib on overall survival in non small cell lung cancer patients: is the post progression survival a new paradigm? 151
Incidence and preferential localizations of bone metastases: biomolecolar and clinical implications. 149
Emerging targeted therapies for castration-resistant prostate cancer 149
Impact of single-nucleotide polymorphisms in genes coding for folate pathway enzymes on efficacy/toxicity of gemcitabine and pemetrexed based therapy in advanced non small cell lung cancer (NSCLC): new prospectives for old markers. 147
Epidermal growth factor receptor (EGFR) G719C mutation as new determinant of long term survival and response in patients with non small cell lung cancer treated with erlotinib: a case report. 147
Impact of circulating microRNAs mir-22, mir-24 and mir-34a on response to pemetrexed in patients with non small cell lung cancer 146
Pegylated liposomal doxorubicin in combination with gemcitabine in elderly women with locally advanced or metastatic breast cancer: safety and activity results of our clinical experience. 144
Safety and activity of trastuzumab-containing therapies for the treatment of metastatic breast cancer: our long-term clinical experience (GOIM study) 141
NSCLC and HER2: between lights and shadows 141
Benefits and Harms of Lung Cancer Screening by Chest Computed Tomography: A Systematic Review and Meta-Analysis 139
Management of Endocrine and Metabolic Toxicities of Immune-Checkpoint Inhibitors: From Clinical Studies to a Real-Life Scenario 139
The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status 137
Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study 136
Diagnosis and treatment of early and locally advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical Oncology) clinical practice guidelines 133
May the istotype influence the response to pemetrexed in patients with non small cell lung cancer? Preliminary data of our clinical experience. 131
Ruolo del Trastuzumab nel Trattamento Adiuvante del Carcinoma Mammario Operabile. 131
SAFETY AND ACTIVITY OF ERLOTINIB (TARCEVA) IN HEAVILY PRE-TREATED PATIENTS WITH METASTATIC, REFRACTORY NON SMALL CELL LUNG CANCER 130
New biomarkers to predict response to pemetrexed-based chemotherapy in non small cell lung cancer: from 5,10-methylenetetrahydrofolate reductase promises to miRNAs revolution. 130
Gefitinib in lung cancer therapy. Clinical results, predictive markers of response and future perspectives. 129
Molecular and clinical analysis of predictive biomarkers to anti-EGFR inhibitors in metastatic colorectal cancer (mCRC): Interaction among early tumor shrinkage, skin toxicities, and RAS status. 127
Rapid Acquisition of T790M Mutation after Treatment with Afatinib in an NSCLC Patient Harboring EGFR Exon 20 S768I Mutation 125
Safety of trastuzumab, alone or in combination, in elderly patients with HER2-positive breast cancer: A 5-year case series. 124
Ruolo di Trastuzumab nella terapia adiuvante del carcinoma mammario operabile. 120
Neuropsychiatric Adverse Drug Reactions with Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors: An Analysis from the European Spontaneous Adverse Event Reporting System 117
Ruolo del Trastuzumab nel Trattamento Adiuvante del Carcinoma Mammario Operabile 116
Neoplasie della testa collo nell’ anziano 116
Role of interleukin-23 circulating levels increase in resected colorectal cancer before and after chemotherapy: preliminary data and future perspectives. 114
Rare histotypes of epithelial biliary tract tumors: A literature review 114
Neuropsychiatric adverse drug reactions with oral tyrosine kinase inhibitors in metastatic colorectal cancer: an analysis from the FDA Adverse Event Reporting System 113
Safety of the combination Capecitabine plus Bevacizumab in the treatment of heavily treated advanced colorectal cancer patients: Our experience. 110
Turbe della nutrizione: anoressia e cachessia. 110
Role of MTHFR polymorphisms as predictive markers of acute toxicity during 5-fluorouracil based chemotherapy for colorectal cancer: Preliminary data. 108
Safety and clinical activity of trastuzumab (TSM) containing therapies in heavily pretreated patients with metastatic breast cancer (MBC): A five-year experience 107
Listening understanding and acting (lung): Focus on communicational issue in thoracic oncology 107
Molecular profiling in Italian patients with advanced non-small-cell lung cancer: An observational prospective study 104
Treatment of advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical Oncology) clinical practice guidelines 103
Immune Checkpoint Inhibitors and the Kidney: A Focus on Diagnosis and Management for Personalised Medicine 100
Cardiotoxicity Induced by Anticancer Therapies: A Call for Integrated Cardio-Oncology Practice 99
Neoplasie della Testa e del Collo nell'anziano 96
Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small-cell lung cancer. 96
POLIMORPHISM OF METHYLENE-TETRAHYDROFOLATE REDUCTASE AND RISK OF LUNG AND COLON-RECTAL CANCER: A CASE CONTROL STUDY 95
Temozolamide plus oral vinorelbine in the treatment of brain metastases from solid tumours in heavily pre- treated patients. 95
Safety and activity of trastuzumab (TRA) containing therapies as treatment of metastatic breast cancer(MBC): a five year experience. 93
“Lunga stazionarietà di malattia e clinical benefit con erlotinib in un paziente anziano, forte fumatore, affetto da carcinoma squamoso del polmone”. 92
Invecchiamento e cancro. 88
Use of nivolumab in elderly patients with advanced Non-Squamous NSCLC: results from the Italian Expanded Access Program (EAP) 87
Is multidisciplinary management possible in the treatment of lung cancer? A report from three Italian meetings 87
Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab 85
Renal Disorders with Oral Tyrosine Kinase Inhibitors in Metastatic Colorectal Cancer: An Analysis from the FDA Adverse Event Reporting System Database 84
Negative Hyperselection in Metastatic Colorectal Cancer for First-Line Anti-EGFR Therapy: A Narrative Review 83
Unveiling cardiovascular and respiratory toxicities with monoclonal antibodies in multiple myeloma: disproportionality analysis from the FDA Adverse Event Reporting System 83
Prediction and validation of GUCA2B as the hub-gene in colorectal cancer based on co-expression network analysis: In-silico and in-vivo study 82
FGFR a promising druggable target in cancer: Molecular biology and new drugs 81
Treatment option for small cell lung cancer: does lanreotide represent a new choice? 78
Re-treatment with gefitinib or treatment with erlotinib after gefitinib failure in responsive non small cell lung cancers: new strategies to overcome acquired resistance. 78
Totale 14.914
Salva come PNG Salva come JPEG
Categoria #
all - tutte 49.390
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 49.390
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022549 0 0 0 0 28 7 29 27 5 163 90 200
2022/20231.841 128 179 74 157 136 184 49 129 724 9 49 23
2023/2024495 25 80 32 29 23 175 60 4 2 21 8 36
2024/20252.055 34 22 34 112 104 82 57 451 473 156 192 338
2025/20266.718 332 378 474 431 551 1.403 862 914 824 293 110 146
2026/20271.658 184 728 318 399 29 0 0 0 0 0 0 0
Totale 15.497